Skip to main content

Table 2 Major clinical trials on nivolumab and pembrolizumab for treatment of Hodgkin lymphoma

From: Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

Study

Trial name

Phase

N

Setting

Treatment

Efficacy results

Ansell et al. 2015 [52]

CheckMate 039 (arm 1, expansion cohort)

1

23

Relapsed or refractory

Nivolumab 3 mg/kg Q2W for up to 2 years

ORR 87% (CR 17%, PR 70%)

PFS rate at 24 weeks 86%

Younes et al. 2016 [54,55,56]

CheckMate 205 (cohort B)

2

80

Relapsed or refractory after ASCT and brentuximab vedotin

Nivolumab 3 mg/kg Q2W

ORR 68% (CR 13%, PR 55%)

12-month PFS rate 54.6%, OS rate 94.9%

Median PFS 14.7 months

Armand et al. 2018 [56]

CheckMate 205 (cohorts A and C)

2

Cohort A: 63

Cohort C: 100

Cohort A: relapsed or refractory, brentuximab vedotin naïve

Cohort C: relapsed or refractory after brentuximab vedotin

Nivolumab 3 mg/kg Q2W

Cohort A:

ORR 65% (CR 29%)

Median DOR 20.3 months

Median PFS 18.3 months

Cohort C:

ORR 73% (CR 12%)

Median DOR 14.5 months

Median PFS 11.9 months

Herbaux et al. 2017 [58]

  

20

Relapsed after Allo-SCT

Nivolumab 3 mg/kg Q2W

ORR 95% (CR 42%, PR 52%)

1-year PFS rate 58.2%, OS rate 78.7%

Ramchandren et al. 2017 [59]

CheckMate 205 (cohort D)

2

51

Newly diagnosed advanced stage

Nivolumab 240 mg biweekly for 4 doses, followed by nivolumab plus AVD for 6 cycles

ORR 84% (CR 80%, PR 4%)

Modified PFS rate at 9 months 94%

Ansell et al. 2016 [60]

CheckMate 039 (arm 2)

1

31

Relapsed or refractory

Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for 4 cycles, followed by nivolumab 3 mg/kg Q2W for up to 2 years

ORR 74% (CR 19%, PR 55%)

Herrera et al. 2017 [62]

 

1/2

62

Relapsed after or refractory to frontline therapy

Nivolumab 3 mg/kg plus brentuximab vedotin 1.8 mg/kg Q3W for up to 4 cycles

ORR 83% (CR 62%)

Armand et al. 2016 [63, 64]

KEYNOTE-013

1b

31

Relapsed or refractory after brentuximab vedotin

Pembrolizumab 10 mg/kg Q2W for up to 2 years

ORR 65% (CR 16%, PR 48%)

median PFS 11.4 months

6-month PFS rate 66%, OS rate 100%

12-month PFS rate 48%, OS rate 87%

Chen et al. 2017 [65]

KEYNOTE-087

2

210

Relapsed or refractory after ASCT and/or brentuximab vedotin

Pembrolizumab 200 mg Q3W for up to 2 years

ORR 69.0% (CR 22.4%, PR 46.7%)

6-month PFS rate 72.4%, OS rate 99.5%

9-month PFS rate 63.4%, OS rate 97.5%

  1. N patient number, Q2W every 2 weeks, Q3W every 3 weeks, AVD adriamycin, vinblastine, dacarbazine, ASCT autologous stem cell transplantation, ORR objective response rate, CR complete response, PR partial response, PFS progression-free survival, OS overall survival